Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer

In the phase III EMERALD trial, treatment with elacestrant significantly improved progression-free survival compared with investigator’s choice in patients with estrogen receptor-positive metastatic breast cancer that progressed on prior endocrine therapies.

Detalles Bibliográficos
Autor principal: Jacobson, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Conference Perspectives: Highlights from SABCS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963147/
https://www.ncbi.nlm.nih.gov/pubmed/35348779
http://dx.doi.org/10.1093/oncolo/oyac015
_version_ 1784677929701081088
author Jacobson, Anne
author_facet Jacobson, Anne
author_sort Jacobson, Anne
collection PubMed
description In the phase III EMERALD trial, treatment with elacestrant significantly improved progression-free survival compared with investigator’s choice in patients with estrogen receptor-positive metastatic breast cancer that progressed on prior endocrine therapies.
format Online
Article
Text
id pubmed-8963147
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-89631472022-03-29 Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer Jacobson, Anne Oncologist Conference Perspectives: Highlights from SABCS In the phase III EMERALD trial, treatment with elacestrant significantly improved progression-free survival compared with investigator’s choice in patients with estrogen receptor-positive metastatic breast cancer that progressed on prior endocrine therapies. Oxford University Press 2022-03-28 /pmc/articles/PMC8963147/ /pubmed/35348779 http://dx.doi.org/10.1093/oncolo/oyac015 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Conference Perspectives: Highlights from SABCS
Jacobson, Anne
Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer
title Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer
title_full Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer
title_fullStr Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer
title_full_unstemmed Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer
title_short Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer
title_sort elacestrant improves progression-free survival after endocrine therapy for estrogen receptor-positive metastatic breast cancer
topic Conference Perspectives: Highlights from SABCS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963147/
https://www.ncbi.nlm.nih.gov/pubmed/35348779
http://dx.doi.org/10.1093/oncolo/oyac015
work_keys_str_mv AT jacobsonanne elacestrantimprovesprogressionfreesurvivalafterendocrinetherapyforestrogenreceptorpositivemetastaticbreastcancer

Ejemplares similares